<DOC>
	<DOC>NCT02906618</DOC>
	<brief_summary>The study involves one dose of LY3039478 given by mouth followed by an intravenous infusion (IV) (via a tube linked to a small needle in the vein) of LY3039478. The results of this study will help to answer the following research questions: - How much LY3039478 gets into the blood stream when given by mouth as a capsule compared to when given by an IV - How long it takes the body to remove the study drug - The safety of LY3039478 and any side effects that might be associated with it Participation in the study is expected to last up to 7 weeks. There will be screening, a single study period, and a follow-up.</brief_summary>
	<brief_title>Study of LY3039478 in Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m²) inclusive Have previously completed or withdrawn from this study or any other study investigating LY3039478, and have previously received the investigational product • Have known allergies to LY3039478, related compounds or any components of the formulation, or history of significant atopy in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>